Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Treasury Shares (2018 - 2025)

Bicycle Therapeutics' Treasury Shares history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 129.46% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 129.46%, while the annual FY2025 figure was $1.5 million, 129.46% up from the prior year.
  • Treasury Shares reached $1.5 million in Q4 2025 per BCYC's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.9 million in Q1 2025 to a low of $187725.0 in Q1 2022.
  • Average Treasury Shares over 4 years is $773486.8, with a median of $563419.0 recorded in 2023.
  • The largest YoY upside for Treasury Shares was 141.08% in 2023 against a maximum downside of 74.11% in 2023.
  • A 4-year view of Treasury Shares shows it stood at $187725.0 in 2022, then soared by 74.11% to $326848.0 in 2023, then skyrocketed by 106.29% to $674262.0 in 2024, then surged by 129.46% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Treasury Shares are $1.5 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025).